Bayer sells testosterone drug rights to Grünenthal for €500m
pharmaphorum
JULY 14, 2022
Grünenthal is paying up to €500 million ($501 million) for rights to Nebido (testosterone undecanoate), which is sold in around 80 countries worldwide for testosterone deficiency and made sales of €117 million last year.
Let's personalize your content